What Ainnocence does

Ainnocence is a California-based AI-native biotech founded in 2021 that develops sequence-based AI platforms for drug discovery and materials design. The company's core technology is a proprietary computationally efficient foundation model using block-circulant FFT layers and κ→1 Hessian conditioning, achieving 3.8× parameter reduction while powering three product pillars: SentinusAI® (biologics — antibodies, proteins, peptides, RNA, cell therapy, and synthetic biology), CarbonAI® (chemistry — small molecules, PROTACs, natural products, formulation, and cosmetic actives), and MaterialAI™ (advanced materials for semiconductors, alloys, and aerospace). The platform screens 10 billion+ compounds per day on a single GPU without requiring experimental 3D protein structures, claiming 10–60% wet-lab hit rates versus the 0.1–1% industry baseline and 80% cost reduction versus traditional high-throughput screening. Validation comes from peer-reviewed Nature Scientific Reports publication (2025), an ACS/C&EN white paper (2025), and 20+ PCT patents.

The company operates a multi-modal revenue model: (1) platform subscription licensing of its AI engines to pharma, biotech, CROs, cosmetics, and materials companies; (2) fee-for-service design campaigns where Ainnocence delivers wet-lab-ready lead candidates on a per-program or milestone basis; (3) co-development and strategic partnerships (exemplified by the January 2026 Phase Advance collaboration) with milestone payments and potential downstream royalties; and (4) B2B SaaS for cosmetics and materials R&D. Go-to-market combines enterprise field sales with consulting-style discovery, a self-service portal at app.ainnocence.com for mid-market adoption, scientific publication-driven inbound, and the JP Morgan Healthcare Conference as a key deal-closing venue. The company reports 1–10 employees across Mountain View HQ and Boston, with no disclosed funding rounds to date, and is led by Founder/CEO Dr. Lurong Pan (ex-Bill & Melinda Gates Foundation Senior Investigator).

Name

Ainnocence

Legal name

Ainnocence Inc.

Website

https://ainnocence.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Ainnocence is an AI-native biotech developing sequence-based foundation models for biologics, small-molecule, and materials discovery, serving pharma, biotech, cosmetics, and semiconductor customers via platform licensing, fee-for-service, and co-development partnerships.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• AI drug discovery
• Therapeutic antibody design
• Small molecule discovery
• Materials science AI
• Computational biology

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Platform Licensing: Ainnocence licenses its AI platforms (SentinusAI, CarbonAI, MaterialAI, etc.) to pharmaceutical, biotech, and materials companies. This is the primary revenue model, targeting enterprise customers through annual or multi-year subscription contracts.
2. Fee-for-Service (FFS) Design Campaigns: Per-project or per-campaign design engagements where Ainnocence applies its AI platforms to specific therapeutic programs, delivering wet-lab-ready lead candidates. Charged on a per-program or milestone basis.
3. Co-Development / Strategic Partnerships: Joint development arrangements with pharmaceutical partners where Ainnocence contributes AI-driven drug design capabilities, often tied to milestone payments and downstream royalties. The Phase Advance collaboration exemplifies this model.
4. B2B SaaS for Beauty and Materials R&D: Platform subscriptions and usage-based access for cosmetic brands and materials companies (e.g., CosmeticAI for beauty R&D, MaterialAI for semiconductor and chemical companies), uncorrelated to pharmaceutical revenue streams.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Ainnocence develops three AI-driven platform pillars for therapeutic and materials R&D: SentinusAI for biologics (antibodies, proteins, peptides, RNA, cell therapy, synthetic biology), CarbonAI for chemistry (de novo small molecules, natural products, synthesis planning, formulation, cosmetic actives), and MaterialAI for advanced materials (alloys, semiconductors, crystals). All three are powered by a proprietary computationally efficient foundation model using block-circulant FFT layers and operate on sequence representations rather than requiring experimental 3D protein structures. The platforms are licensed to pharma, biotech, CROs, cosmetics, and semiconductor customers via subscription, fee-for-service design campaigns, and co-development partnerships.

Product overview

Ainnocence operates a platform-plus-modules architecture organized around three core AI pillars: biologics, chemistry, and materials. The flagship biologics platform SentinusAI® (protein/antibody design engine) includes five integrated modules: Antibody Studio, Peptide Studio, RNA Studio, Cell Studio, and SynBio Studio. The chemistry platform CarbonAI® (small molecule design engine) integrates SynMagic™ for retrosynthesis planning alongside modules for natural products, synthesis, formulation, and cosmetic actives. MaterialAI™ provides a separate AI materials discovery pillar. All three platforms share a proprietary computationally efficient foundation model as the core technology engine. Additional products include SenseAI® (RNA therapeutics), BioSynthAI® (synthetic biology), FormulaAI® (formulation optimization), NatmolAI® (natural products), CellulaAI® (cell therapy), PeptideAI® (peptide design), and CosmeticAI® (cosmetic ingredients). The company was founded in 2021 in California and serves customers across big pharma, biotech, CROs, cosmetics, semiconductors, and chemicals sectors.

Differentiator

Problem solved

Functional benefit

Brands

• SentinusAI: AI platform for de novo protein design and antibody engineering using deep learning to predict and optimize protein structures.
• CarbonAI
• CellulaAI
• NatmolAI
• PeptideAI
• BioSynthAI
• FormulaAI
• MaterialAI
• CosmeticAI
• SenseAI
• SynMagic

Products and services

• SentinusAI® End-to-end AI platform for therapeutic antibody and biologics discovery operating on protein and DNA sequence data. Built on a proprietary up-to-1-billion-parameter transformer-based protein foundation model trained on 53.5M+ sequences and 4.04M+ antibody screening datapoints. Achieves 85.7% affinity maturation success across 42 antibody projects and 10–60% wet-lab hit rates versus an industry baseline of 0.1–1%. Includes Product Modules: Antibody Studio (IgG, Fab, scFv, VHH design and affinity maturation), Peptide Studio (cyclic, stapled, GLP-1 analogs), RNA Studio (mRNA codon optimization, siRNA design), Cell Studio (cell line engineering, genome screening), and SynBio Studio (gene design, strain optimization). Sold via platform subscription, fee-for-service design campaigns, and co-development licensing to biopharma, biotech, peptide, RNA therapeutics, and cell therapy customers.
• CarbonAI® End-to-end molecular chemistry platform for de novo small-molecule and PROTAC drug design and discovery, trained on a 2.02B-entry chemical foundation model with 600K molecular generation, 564K target binding, and 267,872 ADMET datapoints. Capabilities include virtual screening of up to 10 billion compounds within hours, scaffold hopping, multi-objective optimization, and the SynMagic retrosynthesis planning module with 95% synthesis success rate. Includes Product Modules: Molecule Design, Natural Products (800K+ NP database and TCM modernization), Synthesis Planner, Formulation Engine, and Cosmetic Actives. Sold to pharma, biotech, CROs, specialty chemicals, and cosmetics customers via subscription licensing and fee-for-service design campaigns.
• MaterialAI™ AI-based platform for advanced materials discovery and optimization, operating on 9.04M material entries across six categories including 1.4M experimental crystals, 5.475M DFT-relaxed inorganics, 1.3M catalyst surfaces, 33K superconductor entries, 700K organic/organometallic entries, and 132K ML benchmark splits. Capabilities include alloy and composite design (high-performance alloys, functional materials, nanomaterials), semiconductor materials (polyimide FCCL, TPU elastomers, process optimization), and crystal structure prediction (stability, phase prediction, process routes). Sold to semiconductor manufacturers, chemical companies (BASF, Dow, DuPont), battery, and aerospace customers via platform licensing and project-based consulting, with revenue uncorrelated to the pharmaceutical pillars.
• Fee-for-Service Design Campaigns Per-program or per-campaign design engagements in which Ainnocence applies SentinusAI, CarbonAI, MaterialAI, and related modules to specific therapeutic or materials programs, delivering wet-lab-ready lead candidates. Billed on a per-program or per-milestone basis with milestones tied to design, screening, and validation outcomes. Targets pharma, biotech, CRO, and specialty chemical customers that need expert execution on a specific program rather than a platform license.
• Co-Development Strategic Partnerships Joint development arrangements with pharmaceutical and clinical partners in which Ainnocence contributes AI-driven drug design capabilities and the partner contributes development, clinical, or commercial capabilities. Structured with milestone payments and downstream royalties. The Phase Advance collaboration is the flagship example, integrating Ainnocence's AI-driven drug design with predictive clinical outcome modeling to reduce development timelines by over 50%.

Quantifiable outcome

• Up to 80% reduction in early drug discovery cost and time
• +7 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature10 records

Partnerships

One partnership is on record.

• Phase AdvancecoreStrategic or Co-development Partner · 29 January 2026Industry-first AI collaboration integrating Ainnocence's AI-driven drug design capabilities with Phase Advance's predictive clinical outcome modeling. The partnership aims to reduce drug development timelines by over 50% and lower clinical trial failure rates. Addresses critical failure points where approximately 95% of drug candidates fail before preclinical research and 98% fail Phase 1 trials. The collaboration was finalized at the JP Morgan Healthcare Conference and targets better early-stage decisions before molecules enter the clinic.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Insilico Medicine: AI-driven drug discovery platform operating across small molecules, biologics, and synthetic biology with its own pipeline and Pharma.AI platform — directly comparable to Ainnocence's three-pillar AI platform model.
• Recursion Pharmaceuticals: AI-enabled drug discovery combining high-throughput biology with machine learning across multiple therapeutic areas — competes for the same enterprise pharma AI discovery budget as Ainnocence.
• Schrödinger, Inc. Physics-based and AI/ML molecular simulation platform (LiveDesign) used by major pharma for small molecule discovery — directly competes with Ainnocence's CarbonAI chemistry pillar.
• Isomorphic Labs: Alphabet-backed AI drug discovery spin-out leveraging DeepMind's AlphaFold — directly competes in AI biologics design where Ainnocence's sequence-first approach positions as a structural-data-independent alternative.
• Exscientia: AI-driven small molecule discovery platform with multiple pharma partnerships and an internal pipeline — comparable business model targeting the same enterprise pharma customers as CarbonAI.
• Atomwise: AI small-molecule design platform using structure-based and convolutional neural networks — competes head-to-head with Ainnocence's CarbonAI in virtual screening and lead generation.
• XtalPi: AI + quantum physics drug discovery platform serving pharma across small molecules and crystal prediction — overlaps with both Ainnocence's CarbonAI chemistry and MaterialAI materials pillars.

Emerging players

• Cradle: AI platform for protein engineering and biologics design focused on sequence-based generative models — directly comparable to Ainnocence's SentinusAI antibody/protein design capabilities.
• Iambic: AI-driven drug discovery combining physics and ML for small molecule and biologics design — emerging competitor with overlap in both chemistry and biologics pillars of Ainnocence's platform.

Regional players

• Citrine Informatics: AI platform for materials and chemicals R&D — comparable to Ainnocence's MaterialAI in serving semiconductor, chemical, and battery customers, though focused on industrial vs pharmaceutical materials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Ainnocence

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ainnocence